EMEA-002942-PIP02-20 - paediatric investigation plan

Peptide derivative of glucagon-like-peptide 1 and glucagon with fatty acid side chain

Key facts

• Active Substance:
  Peptide derivative of glucagon-like-peptide 1 and glucagon with fatty acid side chain
• Therapeutic area:
  Gastroentology-Hepatology
• Decision number:
  P/0173/2022
• PIP number:
  EMEA-002942-PIP02-20
• Pharmaceutical form(s):
  Solution for injection in pre-filled syringe
• Condition(s) / indication(s):
  Treatment of obesity
• Route(s) of administration:
  Subcutaneous use
• Contact for public enquiries:

  Boehringer Ingelheim International GmbH

  E-mail: [e-mail]; Tel: [phone]

• Decision type:
  P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
• Decision date:
  13/05/2022

Decision

P/0173/2022 : EMA decision of 13 May 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for peptide derivative of glucagon-like-peptide 1 and... (EMEA-002942-PIP02-20)

AdoptedReference Number: EMA/204429/2022